Panbela Therapeutics logo
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Our Science
    • Overview of SBP-101
    • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Newsroom
    • Press Releases
    • Events & Presentations
  • Investor Relations
    • Corporate Governance
    • Financial Information
    • Annual Reports & Proxy Statements
    • Investor Contact Info
  • Contact

Financial Information

  • Overview
  • Corporate Governance
  • Financial Information
  • Annual Reports & Proxy Statements
  • Investor Contact Information
SEC and XBRL Filings »

Quick Links

  • Home
  • About Us
  • Our Science
  • Newsroom
  • Investor Relations
  • Contact

Contact

ir@panbela.com
 
Sign up to receive press releases via email:

News & Events

Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Schedules Conference Call on 8/15/22 to Report 2022 2nd Quarter Financial Results

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

Copyright ©2022 Panbela Therapeutics, Inc. All Rights Reserved.